RLMD · Relmada Therapeutics, Inc. · Executive Compensation
$2.90
+0.04 (+1.40%)
At close · Nov 19
Return incl. dividend (before tax)
Play latest call
Q3 2026 earnings call transcript
Market Cap
$304.61M
Shares
106.69M
Volume · Nov 19
224.8K
Avg daily vol (3M)
1.41M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
No Compensation Data
No Summary Compensation Table has been imported from this company's proxy statements yet.
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Charles Ence | Chief Accounting and Compliance Officer | Appointed | 2025-12-15 |
| Maged Shenouda | Chief Financial Officer | Appointed | 2025-12-15 |
| Paul Kelly | Chief Operating Officer | Appointed | 2025-12-15 |
| Paul Kelly | Chief Operating Officer | Appointed | 2025-01-06 |
|
Eric Schmidt
“Dr. Schmidt’s resignation is not due to any disagreement with the Company, the Company’s management or the Board on any matter relating to the Company’s operations, policies or practices.”
|
member of the Board of Directors | Resigned | 2023-09-06 |
| Sergio Traversa | Class II Director | Appointed | 2023-05-25 |
| Charles J. Casamento | Class II Director | Appointed | 2023-05-25 |
| Fabiana Fedeli | Class I director | Appointed | 2023-01-17 |
| Eric Schmidt | Director | Appointed | 2022-06-01 |
Leadership
- Sergio Traversa CEO, Board Member
- Charles J. Casamento Chairman, Board Member
- Maged Shenouda CFO
- Paul Kelly COO, Board Member
- Charles Ence Chief Accounting Officer
- Eric Schmidt Board Member
- Fabiana Fedeli Board Member
- John Glasspool Board Member
Key facts
CIK
1553643
CUSIP
75955J402
13F (30d)
150 filings
132 filers
Visit website
Investor relations